Treatments of unruptured brain arteriovenous malformations: a systematic review and meta-analysis

Renjie Liu, MMa, Yongle Zhan, MMb, Jianmin Piao, MDa, Zhongxi Yang, MDa, Yun Wei, MMa, Pengcheng Liu, MMa, Xuan Chen, MDab,*, Yu Jiang, PhDb

Abstract

Background: The best therapeutic option for unruptured brain arteriovenous malformations (bAVMs) patients is disputed.

Objective: To assess the occurrence of obliteration and complications of patients with unruptured bAVMs after various treatments.

Methods: A systematic literature search was performed in PubMed, EMBASE, Web of Science, and so on to identify studies fulfilling predefined inclusion criteria. Baseline, treatment, and outcomes data were extracted for statistical analysis.

Results: We identified 28 eligible studies totaling 5852 patients. The obliteration rates were 98% in microsurgery group (95% confidence interval (CI): 96%–99%, I² = 74.5%), 97% in surgery group (95%CI: 95%–99%, I² = 18.3%), 87% in endovascular treatment group (95%CI: 80%–93%, I² = 0.0%), and 68% in radiosurgery group (95%CI: 66%–69%, I² = 92.0%). The stroke or death rates were 1% in microsurgery group (95%CI: 0%–2%, I² = 0.0%), 0% in surgery group (95%CI: 0%–1%, I² = 0.0%), 4% in endovascular treatment group (95%CI: 0%–8%, I² = 85.8%), and 3% in radiosurgery group (95%CI: 3%–4%, I² = 82.9%). In addition, the proportions of hemorrhage were 2% in microsurgery group (95%CI: 1%–4%, I² = 0.0%), 23% in endovascular treatment group (95%CI: 7%–39%), and 12% in radiosurgery group (95%CI: 12%–13%, I² = 99.2%). As to neurological deficit, the occurrence was 9% in microsurgery group (95%CI: 6%–11%, I² = 94.1%), 20% in surgery group (95%CI: 13%–27%, I² = 0.0%), 14% in endovascular treatment group (95%CI: 10%–18%, I² = 64.0%), and 8% in radiosurgery group (95%CI: 7%–9%, I² = 66.6%).

Conclusions: We found that microsurgery might provide lasting clinical benefits in some unruptured bAVMs patients for its high obliteration rates and low hemorrhage. These findings are helpful to provide a reference basis for neurosurgeons to choose the treatment of patients with unruptured bAVMs.

Abbreviations: ARUBA = a randomized trial of unruptured cerebral arteriovenous malformation, bAVMs = brain arteriovenous malformations, CI = confidence interval, DSA = digital subtraction angiography, MINORS = Methodological Index for Non-Randomized Studies, mRS = modified Rankin Scale, non-RCTs = non-randomized controlled trials, NOS = Newcastle–Ottawa Scale, RCTs = randomised controlled trials, RIC = radiation-induced change, SRS = stereotactic radiosurgery.

Keywords: complications, meta-analysis, obliteration, treatment, unruptured brain arteriovenous malformations

1. Introduction

Unruptured brain arteriovenous malformations (bAVMs) is a complex vascular disease with estimated annual hemorrhage rates of 1%–4%. It presents a substantial burden for patients because of the potential for serious neurological complications or death. Even though the annual hemorrhage rate is relatively low, the mortality rate after the first hemorrhage is as high as 10%. After 3 months, there is an additional 20% mortality with patients who survive. The increasing use of imaging technology has increased the detection rates of unruptured bAVMs and has inevitably raised the question of their treatments.

The treatments of unruptured bAVMs include surgical resection, radiosurgery, endovascular treatment, medical management group, or any combination of the modalities above. However, different treatments may cause related complications in various degrees. Mohr et al[5] conducted a randomized trial of unruptured cerebral arteriovenous malformation (ARUBA) and found that in terms of death or stroke prevention, the medical management group was superior to the treatment group. However, the potential long-term benefits from intervention could not be estimated on account of the early termination of the
trial. Meanwhile, Rutledge et al. found that the risk of stroke or death (HR: 1.34, 95% CI: 0.12–14.53, P = .81) and degree of clinical impairment among patients with treatment group were lower than that of the previous study. Endovascular treatment, less invasive treatment for vascular diseases, is now widely applied worldwide. However, as a stand-alone treatment, it has been shown to be generally incomplete. A trial showed 117 bAVMs patients were treated with Onyx embolization, in which, only 23 patients achieved complete obliteration. Radiosurgery, although effective in many cases with less common short-term risks than other treatment modalities, requires a few years to achieve nidus obliteration, and the risk of hemorrhage can be slightly increased during the period between treatment and obliteration. Moreover, the longer, continuous risks of radiation, which may occur even >10 years after treatment, are still largely unknown. Microsurgery, as an essential treatment of unruptured bAVMs, provides immediate benefits and eliminates the risk of further lifetime hemorrhage. A study showed that good outcomes could be achieved by microsurgical resection in patients with Spetzler–Martin grade I–II unruptured bAVMs. However, it is challenging to treat patients with S–M grade IV–V unruptured bAVMs. Therefore, the best therapeutic option for unruptured bAVMs patients is still a controversial subject among cerebrovascular neurosurgeons.

At present, there is lacking of high-quality meta-analysis concerning which treatment is better for unruptured bAVMs. And the debate exists in the most favorable therapeutic approach. Furthermore, most patients diagnosed with unruptured bAVMs experience partially disabling symptoms including seizures and headaches, which can reduce their quality of life to some extent. Therefore, we conducted a meta-analysis to explore the best treatment for unruptured bAVMs patients and to evaluate these methods.

In this systematic review, we systematically collected all relevant evidence and conducted a meta-analysis to reported the combined obliteration rates of obliteration, stroke or death, hemorrhage, and neurological deficit after microsurgery, endovascular treatment, and surgery. The present study aims to investigate the advantages and disadvantages among different treatments for unruptured bAVMs patients, and to provide a more reliable basis for neurosurgeons to choose clinical treatments.

2. Methods

2.1. Literature search and inclusion criteria

We conducted this systematic review and meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement. Ethical approval is inapplicable for this study. A systematic literature search was performed through April 1, 2020, in PubMed, EMBASE, Web of Science, and clinical trials registration system (http://www.ClinicalTrials.gov) and so on with the following MeSH terms: unruptured bAVMs (unruptured intracranial arteriovenous malformations/unruptured brain arteriovenous malformation) AND terms for treatment (surgery or microsurgery or radiosurgery or endovascular treatment or embolization/artificial embolism).

After screening by title and abstract, only studies that met the following criteria could be included: (1) original articles with full text; (2) patients with unruptured bAVMs received 1 kind of treatments; and (3) reported the proportion of at least 1 outcome, such as obliteration, stroke/death, hemorrhage, neurological deficit, and so on. We have excluded studies with overlapping published data from the same institution. Review articles, letters, editorials, comments, case reports, and technical reports were excluded.

What’s more, studies reporting other kinds of vascular malformations including ruptured bAVMs, dural arteriovenous fistula, and cavernous malformations were also excluded. All retrieved articles were independently screened by 2 authors (RJL and YLZ) according to the above selection criteria, and discrepancies on whether to include a study were resolved by discussion.

2.2. Data extraction

One author (RJL) extracted the following data, when available, from selected studies of the included articles: a total number of patients, average age, mean or median duration of follow-up, proportions of obliteration, annual hemorrhage, neurological deficit, stroke, or death, functional outcomes, radiation-induced change (RIC) and other complications after treatments. To ensure accuracy, another 2 authors (YLZ and JMP) reviewed the data collected and formatted separately and compared it with the source material. Disagreements on data extraction were resolved through consensus and, if needed, by consulting the senior author (XC and YJ).

2.3. Quality assessment

Two authors (ZXY and YW) independently assessed the risk of bias and graded the quality of all the included studies. The Cochrane risk of bias tool, Methodological Index for Non-Randomized Studies, and Newcastle-Ottawa Scale were used to assess the bias and quality of randomized controlled trials (RCTs), non-RCTs, and cohort studies, respectively. Studies with higher scores represented higher quality.

2.4. Statistical analysis

The pooled rate with its 95% confidence interval (CI) was the effect size to estimate the proportion of obliteration and complications after treatment. Inter-study heterogeneity was assessed by statistics with significance set at the P < .10 level. We also applied the I² statistic to estimate the heterogeneity as low (<25%), moderate (25%–75%), and high (>75%). Effect size with its 95%CI was calculated with a random-effects model when heterogeneity was considerable among studies; otherwise, the fixed-effects model was used. Subgroup analyses were conducted stratified by continent, study duration, time of follow-up, study quality, study design, and publication characteristics. To evaluate the impact of different subgroups on the pooled effect estimates, meta-regression was additionally performed. What’s more, sensitivity analyses were also conducted to evaluate whether any single study dominated the results of the meta-analysis when the pooled results had high heterogeneity. Finally, we constructed funnel plots and Egger tests to assess the possibility of publication bias for the main outcomes with significance at the P < .05. All the statistical analyses were performed using STATA 15.0 (Stata Corporation, College Station, TX, USA).

3. Results

3.1. Description of the included studies

The steps of our systematical search were shown in Figure 1. Through a systematical literature search, a total of 3892 potentially relevant studies were identified. After duplication-
checking, title and abstract screening, and full-text review, 28 full-text studies including 5852 patients were included in the final analysis. The characteristics of the included studies were summarized in Table 1. The present meta-analysis included 4 RCTs, 16 non-RCTs, and 8 cohorts studies, and 11 studies reached high quality. All studies were published between 2012 and 2020, among which, 18 were conducted in North America, 6 in Asia, and 4 in Europe. Duration and follow-up of the included studies ranged from 1989 to 2017, and 6 days to 14.1 years. As to types of treatment, 16 studies reported on radiosurgery, 4 on microsurgery, 9 on endovascular treatment, and 4 on surgery. All the included studies looked for outcomes such as obliteration rate and complications after treatment.

Figure 1. Flowchart demonstrating the literature review process. After duplication-checking, title and abstract screening, and full-text review, 28 studies fulfilled the predefined inclusion criteria and were included in the meta-analysis.
| Study       | Location of study | Year       | Study design                | Follow-up         | Age (y)       | Gender | Simple size (n) | Therapy                  | I  | II | III | IV | V  | Outcomes (n)                                                                 | Quality evaluation |
|------------|-------------------|------------|-----------------------------|-------------------|---------------|--------|----------------|----------------------------|----|----|-----|----|----|--------------------------------------------------------------------------------|------------------|
| Qureshi 2020[14] | US                | RCT        | 11.8 ± 9.4 mo               | 43.7 ± 11.1 yr    | Male (n = 14) | 26     | Endovascular treatment | Radiosurgery              | 7  | 10 | 8   | 1  |     | Stroke, death                                                                   | High             |
| Chen 2020[13]  | US                | Cohort study | 80.8 ± 59.4 mo            | 13.5 ± 3.7        | Male (n = 62) | 101    | Radiosurgery     |                             | 9  | 39 | 36  | 14 | 3   | Hemorrhage, death, permanent RIC, obliteration, radiological RIC, symptomatic RIC | High             |
| Ozpar 2019[15] | Turkey            | NRCT       | 26                          | Endovascular treatment |              |         |                  |                             |    |    |     |     |     | Intracranial hemorrhage, neurologic deficits, death                           | Medium            |
| Chen 2019[16]  | US                | Cohort study | 8.7 ± 13.2 mo             | 35.9 ± 14.1       | Male (n = 6) | 15     | Microsurgery     |                             | 2  | 8  | 3   | 2  | 0   | Obliteration, neurologic deficits, intracranial hemorrhage                    | High             |
| Olsan 2018[17] | France            | NRCT       | 97.0 ± 54.8 mo            | 38.7 ± 14.1       | Male (n = 9) | 19     | Radiosurgery     | Endovascular treatment     | 2  | 11 | 4   | 2  | 0   | Obliteration, death, mRS score                                                | High             |
| Karlsson 2018 | Singapore         | Cohort study | 6.5 (0.1–25) yr          | 42 (8–90)         | Male (n = 763) | 1351  | Microsurgery     | Radiosurgery               |    |    |     |     |     | Obliteration, hemorrhages, death, neurological deficit                        | Medium            |
| Link 2018[18]  | US                | NRCT       | 33.2 mo                    | 43 ± 1.3          | Male (n = 45) | 2      | Surgery          |                             | 16 | 35 | 29  | 6  | 0   | Obliteration, stroke or death, neurologic deficits, long-term clinical impairment | Medium            |
| Nerva 2018[19] | US                | NRCT       | 3.5 ± 1.9 yr              | 39.9 ± 19.6       | Male (n = 29) | 41     | Radiosurgery     | Endovascular treatment     | 4  | 13 | 11  | 10 | 3   | Obliteration, intracranial hemorrhage, neurologic deficits                    | Medium            |
| Yang 2019[20]  | US                | NRCT       | 7.7 ± 10.8 yr             | 40.2 ± 19.5       | Male (n = 67) | 155    | Endovascular treatment | Radiosurgery              | 52 | 66 | 30  | 7  | 0   | Obliteration, intracranial hemorrhage, neurological deficits                  | Medium            |
| Wong 2017[21]  | Canada            | NRCT       | 36.1 mo                   | 38.5              | Male (n = 187) | 282    | Microsurgery     |                             | 186| 72 | 24  |     |     | Obliteration, seizure outcome, neurological deficits, intracranial hemorrhage, hydrocephalus, infections, mRS score | Medium            |
| Tong 2017[22]  | China             | NRCT       | 50.0 ± 23.2 mo            | 30.5 ± 12.2       | Male (n = 187) | 282    | Radiosurgery     |                             |    |    |     |     |     | Obliteration, intracranial hemorrhage, radiological RIC, symptomatic RIC, permanent RIC | Medium            |
| Starke 2017[23] | US                | Cohort study | 81.1 ± 55.5 mo            | 12.6 ± 3.7        | Male (n = 112) | 112    | Radiosurgery     |                             |    |    |     |     |     | Obliteration, intracranial hemorrhage, radiological RIC, symptomatic RIC, permanent RIC | Medium            |
| Ding 2017[24]  | US                | NRCT       | 90.5 ± 63.3 mo            | 41.8 ± 14.2       | Male (n = 187) | 232    | Radiosurgery     |                             | 49 | 183|     |     |     | Obliteration, stroke or death, intracranial hemorrhage, Radiologic RIC         | Medium            |
| Ding 2017[25]  | US                | Cohort study | 33.0 mo                  | 34.7 (3.5–81.1)   | Male (n = 483) | 338    | Radiosurgery     |                             | 84 | 323| 436 | 89 | 6   | Obliteration, intracranial hemorrhage, symptomatic RIC                         | Medium            |

(continued)
| Study       | Location of study | Year             | Study design | Follow-up       | Age (y)          | Gender | Simple size (n) | Therapy                  | I | II | III | IV | V | Outcomes (n) | Quality evaluation |
|------------|-------------------|------------------|--------------|----------------|------------------|--------|----------------|--------------------------|---|---|-----|-----|---|--------------|-------------------|
| Singfer 2017[22] | US                | 2001–2014       | NRCT         | 60.0 mo        | 38.0 ± 11.0      | Male (n = 32) | 61           | Endovascular treatment | 11 | 20 | 21  | 8   | 1 | Permanent RIC, death | Medium            |
| Mohr 2017[23]     | US                | 2007–2013       | RCT          | 33.3 (16.3–49.8 mo) | > 18          | Male (n = 114) | 114         | Endovascular treatment | 8  | 16 | 8   | 2   |    | Functional impairment | High              |
| Javadpour 2016[24] | UK                | 2004–2014       | Cohort study | 69 (6–126) mo  | Male (n = 34)   | 34           | Microsurgery | 8                        | 16 | 8  | 2   |    |    | Death or stroke, neurologic deficit, mRS score | High              |
| Hanakita 2016[25] | Japan             | 1990–2005       | NCTR         | 62 (36–102) mo | 39 (30–50)      | Male (n = 151) | 240          | Radiosurgery             | 76 | 95 | 53  | 11  | 5 | Obliteration, intracranial hemorrhage, neurologic deficits, seizures, hemiparesis, dyesthesia, hemianopsia, aphasia | Medium            |
| Ding 2016[26]     | US                | 1997–2014       | NRCT         | 86.2 ± 62.3 mo | 39.7 ± 13.7     | Male (n = 271) | 500          | Radiosurgery             | 49 | 183| 245 | 32  |    | Permanent RIC, death | Medium            |
| Ding 2015[27]     | US                | 1989–2009       | Cohort study | 65.6 (60.3–71.0 mo) | 37.3          | Male (n = 139) | 270          | Radiosurgery             | 46 | 102| 94  | 28  |    | Obliteration, intracranial hemorrhage, symptomatic RIC, permanent RIC, death, neurologic deficits | Medium            |
| Ding 2015[28]     | US                | 1989–2013       | NRCT         | 78.7 ± 51.8 mo | 12.6 ± 3.6      | Male (n = 27) | 51           | Radiosurgery             |    |    |     |     |    | Obliteration, intracranial hemorrhage, symptomatic RIC, permanent RIC, post-radiosurgery cyst formation | Medium            |
| Morgan 2015[29]   | Finland           | 1989–2014       | Cohort study | 3.0 y (6d–14.1 y) | 33.0 ± 13.0    | Male (n = 64) | 137          | Surgery                  |    |    |     |     |    | Obliteration, neurologic deficits, stroke or death | High              |
| Potts 2015[30]    | US                | 1997–2013       | NRCT         | 1.2 yr (2wk–12.8 yr) | 39.4 ± 15.3    | Male (n = 42) | 112          | Surgery                  | 37 | 75 |     |     |    | Obliteration, stroke or death, mRS score | Medium            |
| Wang 2014[31]     | Taiwan            | 1994–2005       | NRCT         | 104 ± 98.5 mo  | 28 ± 28.07     | Male (n = 66) | 42           | Radiosurgery             |    |    |     |     |    | Obliteration, adverse effect, intracranial hemorrhage | Medium            |
| Mohr 2014[32]     | Germany           | 2007–2013       | RCT          | 32.9 ± 19.2 mo | 45 ± 12        | Male (n = 66) | 114          | Endovascular treatment | 32 | 44 | 28  | 8   |    | Death or stroke, focal deficit, seizure, infection | High              |
| Rutledge 2014[33] | US                 | 2007–2013       | RCT          | 21 mo          | 41             | Male (n = 34) | 15           | Radiosurgery             | 8  | 21 | 21  | 7   | 3 | Stroke or death, mRS score, obliteration | High              |
| Ding 2013[34]     | US                 | 1989–2009       | NRCT         | 86 ± 53 mo     | 36.9 ± 35.8    | Male (n = 222) | 444          | Radiosurgery             | 81 | 167| 163 | 30  | 3 | Obliteration, intracranial hemorrhage, RIC, formation, radiation-induced, neoplasia, new-onset seizures | Medium            |
| Yang 2012[35]     | Korea             | 1997–2006       | NRCT         | 89.9 mo        | 181            | Male (n = 181) | 161          | Radiosurgery             |    |    |     |     |    | Obstruction, seizures | Medium            |

N = number, RIC = radiation-induced change.
3.2. Primary outcome

Twenty-one studies\textsuperscript{[1–3,7,11,16,19–21,23,24,27,28,30–37]} with a total of 5452 patients with unruptured bAVMs reported the obliteration rate after treatment. The highest rate occurred in microsurgery group ($r = 98\%$, 95\%CI: 96\%–99\%, $I^2 = 74.5\%$), followed by surgery group ($r = 97\%$, 95\%CI: 95\%–99\%, $I^2 = 18.3\%$) and endovascular treatment group ($r = 87\%$, 95\%CI: 80\%–93\%, $I^2 = 0.0\%$), and lowest in radiosurgery group ($r = 68\%$, 95\%CI: 66\%–69\%, $I^2 = 92.0\%$) (Fig. 2).

3.3. Secondary outcomes

3.3.1. Stroke/death. Fifteen studies\textsuperscript{[3,5,7,16–18,20,21,25,27–32]} with a total of 3874 patients reported the occurrence of stroke or death after treatment. The highest rate of stroke or death was observed in the endovascular treatment group ($r = 4\%$, 95\%CI: 0\%–8\%, $I^2 = 85.8\%$), followed by the radiosurgery group ($r = 3\%$, 95\%CI: 3\%–4\%, $I^2 = 82.9\%$) and microsurgery group ($r = 1\%$, 95\%CI: 0\%–2\%, $I^2 = 0.0\%$), and lowest in the surgery group ($r = 0\%$, 95\%CI: 0\%–1\%, $I^2 = 0.0\%$) (Fig. 3).

3.3.2. Hemorrhage. Sixteen studies\textsuperscript{[1,2,11,16,19,21–24,27,28,30,33,35,36]} with a total of 4790 patients reported the hemorrhage rate after treatment. The highest rate was 23\% in endovascular treatment group (95\%CI: 7\%–39\%), followed by radiosurgery group ($r = 12\%$, 95\%CI: 12\%–13\%, $I^2 = 99.2\%$), and lowest in microsurgery group ($r = 2\%$, 95\%CI: 1\%–4\%, $I^2 = 0.0\%$) (Fig. 4).

3.3.3. Neurological deficit. Thirteen studies\textsuperscript{[1–3,5,11,18,19,21,23,26,29,30,32]} with a total of 3104 patients reported the occurrence of neurological deficit after treatment. The rate was highest in surgery group ($r = 20\%$, 95\%CI: 13\%–27\%, $I^2 = 0.0\%$), followed by endovascular treatment group ($r = 14\%$, 95\%CI: 10\%–18\%, $I^2 = 64.0\%$) and microsurgery group ($r = 9\%$, 95\%CI: 6\%–11\%, $I^2 = 94.1\%$), and lowest in radiosurgery group ($r = 8\%$, 95\%CI: 7\%–9\%, $I^2 = 66.6\%$) (Fig. 5).

3.4. Tertiary outcomes

Other outcomes with their pooled rates were shown in Table 2. A 44\% and 2\% of patients who received endovascular treatment and radiosurgery developed epilepsy, respectively. In addition, 2\% of patients who received microsurgery or endovascular treatment underwent postoperative infection. As to mRS score, most of the patients in the microsurgery group (88\%) compared with the surgery group (81\%) and endovascular treatment group (54\%) received low scores (0–1) while patients in the endovascular treatment group (22\%) rather than microsurgery group (12\%) and surgery group (12\%) received high scores (≥2).

---

Figure 2. Forest plot of the pooled obliteration rate. Studies reported the obliteration rate of unruptured bAVMs patients after treating were pooled categorized by therapy methods. bAVMs = brain arteriovenous malformations.
What’s more, in the radiosurgery group, 4% of patients had permanent RIC, 34% had radiologic RIC, and 11% had symptomatic RIC.

### 3.5. Subgroup analyses

#### 3.5.1. Continent

Continent-subgroup analysis showed that on obliteration, Asian patients had a higher proportion after radiosurgery ($r=79\%, \ 95\% CI: 65\%–92\%$) and microsurgery treatment ($r=98\%, \ 95\% CI: 97\%–100\%$), while European patients had a higher proportion after endovascular treatment ($r=88\%, \ 95\% CI: 81\%–94\%$) and surgery ($r=98\%, \ 95\% CI: 95\%–100\%$). As to stroke/death, Asian patients had a lower proportion after radiosurgery treatment ($r=1\%, \ 95\% CI: 0\%–3\%$) while European patients had a lower proportion after endovascular treatment ($r=3\%, \ 95\% CI: 1\%–6\%$). In addition, Asian patients had the lowest proportion of getting hemorrhage after microsurgery treatment ($r=2\%, \ 95\% CI: 0\%–3\%$). As for the neurological deficit, Asian patients also had the lowest proportion after microsurgery treatment ($r=5\%, \ 95\% CI: 3\%–8\%$) and radiosurgery treatment ($r=8\%, \ 95\% CI: 6\%–9\%$) (Table S1, Supplemental Digital Content, http://links.lww.com/MD2/A228).

#### 3.5.2. Study duration, time of follow-up, study quality, study design, and publication characteristics

We also conducted subgroup analyses stratified by study duration, time of follow-up, study quality, study design, and publication characteristics. We found that studies with more than 10 years of duration reported a higher proportion of obliteration on radiosurgery treatment and a lower proportion of other complications (Table S2, Supplemental Digital Content, http://links.lww.com/MD2/A229). The same results could also be found in studies with a longer time of follow-up in the follow-up subgroup (Table S3, Supplemental Digital Content, http://links.lww.com/MD2/A230). In addition, a lower proportion of neurological deficit was observed in the microsurgery group with a longer time of follow-up (Table S3, Supplemental Digital Content, http://links.lww.com/MD2/A230). As to study quality subgroup, higher proportions of obliteration and other complications, and lower proportions of hemorrhage were found in high-quality studies (Table S4, Supplemental Digital Content, http://links.lww.com/MD2/A231). Studies with NRCT design seemed to report higher proportions of obliteration but lower complications (Table S5, Supplemental Digital Content, http://links.lww.com/MD2/A232). After stratified by publication characteristics, studies published in journals with high quality reported higher proportions of obliteration and hemorrhage, and lower proportions of stroke/death (Table S6, Supplemental Digital Content, http://links.lww.com/MD2/A233).

### 3.6. Meta-regression

Results of meta-regression showed that there was a statistical difference regarding hemorrhage rate among different continents on radiosurgery treatment ($P=.023$). However, we did not see
other statistically significant results due to insufficient studies (number of studies) on specific groups (Table S7, Supplemental Digital Content, http://links.lww.com/MD2/A234).

3.7. Sensitivity analysis

Sensitivity analyses were conducted on treatment groups with high heterogeneity. Therefore, the radiosurgery group, microsurgery group, and endovascular treatment group were performed with sensitivity analysis. After the deletion of any single study, we could not see any statistically significant heterogeneity and association changes (Figure S1, Supplemental Digital Content, http://links.lww.com/MD2/A235).

3.8. Publication bias

Publication bias was needed to be examined in pooled results including 7 or more studies. Therefore, funnel plots and Egger tests were conducted to identify publication bias on the main outcomes of the radiosurgery group. We did not identify any significant statistical bias on obliteration rate ($P = .805$), stroke or death ($P = .078$), hemorrhage ($P = .948$), and neurological deficit ($P = .161$) (Figure S2, Supplemental Digital Content, http://links.lww.com/MD2/A236).

4. Discussion

The bAVMs are congenital anomalies of blood vessels that cause intracranial hemorrhage. However, congenital factors cannot fully explain the growth of arteriovenous malformations. Studies have confirmed that the biological behavior of bAVMs is closely related to the changes of high hemodynamic factors.[38] The hemodynamic state of long-term high flow and low resistance directly causes vascular endothelial function damage, leading to a large number of inflammatory cell infiltration around arteriovenous malformations vessels, which leads to inflammatory reaction and oxidative stress reaction. Oxidative stress can play an important role in cerebrovascular diseases, possibly through the damaging of vascular endothelial function.[39,40]

It has been found that there is not only continuous oxidative stress but also a decrease of antioxidants in bAVMs patients. A study reported that when antioxidants decreased, oxidative stress caused more serious damage to malformed blood vessels, resulting in rupture and bleeding of malformed blood vessels.[41]

In addition, vascular endothelial growth factor (vascular endothelial growth factor, VEGF) and basic fibroblast growth factor (basic fibroblast growth factor, BFGF) also played an important role in angiogenesis. As a vascular growth factor, VEGF is mainly involved in the formation, growth, and differentiation of blood vessels. Studies have shown that VEGF plays a certain role in the growth of malformed vascular mass after embolization.[42] In the process of promoting the pathological angiogenesis of bAVMs, more VEGF promotes more neovascularization. And the instability of neovascularization is the direct cause of the vascular mass rupture of bAVMs. Therefore, oxidative stress may stimulate the formation and growth of malformed blood vessels through ERK-HIF-VEGF.
pathway, and the instability of neovascularization further leads to rupture and bleeding of malformed blood vessels.

Regarding the treatment of unruptured bAVMs patients, prior work has documented the effectiveness of the treatment group in terms of death or stroke prevention. However, there were some shortages among these studies, including short-term duration and lacking analyses of the effects of different treatments on patient prognostic indicators. In this study, we systematically estimated the proportion of obliteration and complications after various treatments and found that although radiosurgery, surgery, and endovascular treatment have played essential roles in the management of unruptured bAVMs,

Figure 5. Forest plot of the pooled neurological deficit rate. Studies reported the neurological deficit rate of unruptured bAVMs patients after treating were pooled categorized by therapy methods. bAVMs = brain arteriovenous malformations.

Table 2

| Outcomes                  | Treatment          | Included studies (n) | Patients (n) | Pooled rate (95%CI) | Heterogeneity (I², %) | P value |
|---------------------------|--------------------|---------------------|--------------|---------------------|-----------------------|---------|
| Epilepsy                  | Radiosurgery       | 4                   | 801          | 2% (0%–4%)          | 71.6                  | .014    |
|                           | Endovascular       | 1                   | 114          | 4% (0%–9%)          | –                     | –       |
|                           | treatment          |                     |              |                     |                       |         |
| Postoperative infection   | Microsurgery       | 1                   | 282          | 2% (0%–4%)          | –                     | –       |
|                           | Endovascular       | 1                   | 114          | 2% (0%–5%)          | –                     | –       |
|                           | treatment          |                     |              |                     |                       |         |
| mRS=≤2                    | Microsurgery       | 2                   | 316          | 88% (85%–92%)       | 62.4                  | .103    |
|                           | Endovascular       | 2                   | 87           | 54% (46%–62%)       | 98.0                  | <.001   |
|                           | treatment          |                     |              |                     |                       |         |
| mRS=≥2                    | Microsurgery       | 2                   | 316          | 12% (8%–15%)        | 61.2                  | .108    |
|                           | Endovascular       | 2                   | 87           | 22% (13%–30%)       | 0.0                   | .693    |
|                           | treatment          |                     |              |                     |                       |         |
| Permanent RIC             | Radiosurgery       | 5                   | 1930         | 4% (3%–5%)          | 90.9                  | <.001   |
|                           | Endovascular       | 4                   | 495          | 34% (30%–38%)       | 90.3                  | <.001   |
|                           | treatment          |                     |              |                     |                       |         |

CI = confidence interval, mRS = modified Rankin Scale, n = number, RIC = radiation-induced change.
microsurgery has the highest obliteration rate and the lowest hemorrhage rate. The findings of the present study provide a more reliable basis for clinical practice.

Microsurgery, as an essential treatment of unruptured bAVMs, provides immediate benefits, eliminates the risk of further lifetime hemorrhage,[10] and maybe performed safely in appropriately selected patients. In recent years, studies[43,44] reported hemorrhage rates of 0.18% after microsurgery treatment, 1.7% after radiosurgery treatment, and 1.7% after endovascular treatment, which were consistent with the results of our study. However, this was at the expense of a significantly higher risk of new neurological deficits in the microsurgery group. In other words, in the microsurgery group, the most common reason for failure was a new neurological deficit.[19] However, 1 recent study implied that patients with neurological deficits after microsurgery could recover neurological function over time.[111,19] Endovascular treatment, as a less invasive treatment for vascular diseases, is now widely applied worldwide. It is questioned because people realize that it is not easy to achieve complete elimination. As reported, the introduction of Onyx (Medtronic, Irvine, CA, USA),[45] the latest agent, offered more controllable intranidal dispersion and increased the cure rate of unruptured bAVMs. However, the endovascular treatment also remained associated with substantial complications despite technological advances. A meta-analysis of Onyx[46] has reported that it might increase the rate of permanent neurological deficits and mortality. Unfortunately, we also found that the highest hemorrhage rate (23%) was observed in the endovascular treatment group. The potential mechanism is that embolization can promote angiogenesis and increase radiation resistance or make nidus more irregular and diffuse, making it impossible to eliminate it routinely.[47,48]

Meanwhile, the obliteration rate after endovascular treatment was not as impressive as we would have expected. It may cut off the nidus before resection or reduce the volume of the nidus before stereotactic radiosurgery (SRS).[49] Therefore, endovascular treatment is typically used as preoperative neoadjuvant therapy for either resection or SRS. As for radiosurgery, it is a routine treatment for unruptured bAVMs patients, although with controversial effectiveness and disadvantages.

Ding et al found in their study comprised 938 patients with unruptured bAVMs that bAVMs obliteration was achieved similarly in 65%.[28] In our meta-analysis, we found that complete obliteration rates of bAVMs following a single SRS treatment was 68% demonstrated by digital subtraction angiography (DSA). The mechanism of bAVMs obliteration in the radiosurgery treatment mainly is because it makes progressive intimal thickening, thrombosis of irradiated vessels, and eventual occlusion of the vascular lumen.[50] Moreover, radiosurgery can reduce the frequency and intensity of seizures via some intrinsic effects on the unruptured bAVMs nidus and surrounding areas.[51,52] However, we unfortunately found that after radiosurgery, 4% of patients had permanent RIC, 34% had radiologic RIC, and 11% had symptomatic RIC, which was consistent with Flickinger findings.[53] This might be concerned with the overuse of radiation doses in pursuit of greater obliteration. Besides, we found that surgical treatment was very useful in eliminating the risk of hemorrhage and reducing the volume of the nidus. However, Morgan et al found[54] that the abnormal vessels observed with filling slowly in the DSA immediately after surgery were not always effortless, especially in the absence of apparent arteriovenous shunting. Therefore, although statistically significant, it is not easy to quantify the magnitude of these effects. This is because of the small number of patients and the wide CIs.

The early termination and the short follow-up time were the main limitations of the ARUBA trial, which could cast doubt on the results.[1,6,12,27] Therefore, we analyzed the effect of different follow-up time on treatment outcomes. We found that after an extended follow-up, the risk of stroke or death increased after endovascular treatment, which might be related to the neurological defects and hemorrhage caused by their postoperative.[56] Although the meta-analysis showed that patients in the high-duration subgroup after microsurgery had higher rates of neurological deficits and lower rates of obliteration, we could not draw a certain conclusion. Mainly because with the larger time-span of a study, the heterogeneity of included patients could be increasing. Moreover, medical technology in different periods may have an impact on the prognosis. Due to the immature microsurgical techniques in the earlier period, the occurrence of neurological defects in such patients receiving microsurgery may be higher.[1,11,29] It seems there are inequalities in bAVMs treatment and clinical outcomes between people from different ethnic backgrounds.[1,11,19,26] Continent-subgroup analysis in this study has shown that compared with European patients, Asian patients had a higher obliteration rate and a lower incidence of neurological deficit after microsurgery. However, limited to existing studies, whether Asian bAVMs patients benefit more after microsurgery remains to be confirmed by further high-volume, multicentered, and extensive follow-up controlled trials.

Currently, all of these treatments about unruptured bAVMs may result in high risks of adverse prognosis as we have found. Moreover, with the advent of the era of individual genome sequencing, genotype researches and risk factors assessment of arteriovenous malformation have become more in-depth. Therefore, the biological therapeutic method may be an option with great promise for unruptured bAVMs. Increasing evidence showed that the genetic and environmental factors could jointly affect the occurrence of AVMs. Thomas et al[57] found that DNA methylation in genes connected to vascular development had a vital role in the development of unruptured bAVMs. Chen et al[58] showed that the risk of bAVMs might be related to methylation of the CDKN2A gene. In addition, Nakamura et al[59] suggested that activated macrophages might increase the angiogenesis of PDCN possibly leading to hemorrhage events in unruptured bAVMs. Furthermore, studies have shown that[60,61,62] the increase of VEGF may affect the proliferation and migration ability of vascular endothelial cells, further hyperplasia of malformed blood vessels, or rupture and hemorrhage of blood vessels. Fortunately, VEGFR1 has an anti-angiogenic effect, which can resist angiogenesis induced by VEGF in arteriovenous malformations. Bevacizumab, as an anti-VEGF monoclonal antibody, may inhibit the formation of arteriovenous malformation in the epidermis and brain, and affects the progress of blood malformation vessels. We have reasons to believe that with the further development of unruptured bAVMs genetics, drug design in the future can treat unruptured bAVMs according to its biological characteristics.

The essential limitation of our meta-analysis were that the pooled data available from retrospective, single-center studies with inherent selection and treatment biases. Although the heterogeneity was present in the summary estimates, we have carried out subgroup analyses and sensitivity analyses to explore the potential sources of heterogeneity. But we could not identify the statistical significance by meta-regression among most specific
subgroups due to insufficient studies in each group. Detailed clinical outcomes in terms of hemorrhage, stroke or death, and obliteration were unavailable in these studies.\textsuperscript{[7,22]} Meanwhile, selection of unruptured bAVMs patients for certain treatment options is likely to have been affected by brain AVM characteristics and patient,\textsuperscript{[63]} which may hamper comparison of treatments. Due to the lack of detailed data, we were unable to compare the obliteration rates of various treatments according to the Spetzler–Martin grade and AVM localization. In addition, due to the insufficient eligible studies, we failed to further analyze the effect of different combination therapies combination regimens on patients’ prognosis. Furthermore, many patients were unable to obtain detailed clinical follow-up because the participating institutions were each tertiary referral centers with varying degrees of rigor in follow-up neurology and functional assessment. We also could not determine how many deaths were caused by unruptured bAVMs in patients.

5. Conclusions
Unruptured bAVMs are complex vascular diseases with serious potential neurological complications or death, but the best therapeutic option for unruptured bAVMs patients is still disputed. In this study, we found that microsurgery might provide lasting clinical benefits in some unruptured bAVMs patients for its high obliteration rates and low hemorrhage. However, with the limitations of studies we included, there were still considerable risks and incomplete efficacy in the treatments of unruptured bAVMs. Further prospective multicenter and long-term follow-up controlled trials are essential to address these limitations.

Author contributions
Data curation: Yongle Zhan.
Investigation: Jianmin Piao.
Methodology: Yu Jiang.
Project administration: Renjie Liu.
Resources: Zhongxi Yang, Pengcheng Liu.
Software: Pengcheng Liu.
Writing – original draft: Renjie Liu, Yongle Zhan, Yun Wei.
Writing – review & editing: Jianmin Piao, Xuan Chen, Yu Jiang.

References
[1] Wong J, Slomovic A, Ibrahim G, Radovancevic I, Tymianski M. Microsurgery for ARUBA trial (a randomized trial of unruptured brain arteriovenous malformation)-eligible unruptured brain arteriovenous malformations. Stroke 2017;48:136–44. doi:10.1161/STROKEAHA.116.014660.
[2] Hanakita S, Shin M, Koga T, Igaki H, Saito N. Risk reduction of cerebral hemorrhages. J Neurointerv Surg 2017;9:664–71. doi:10.1136/neurintsurg-2016-012483.
[3] Link TW, Winston G, Schwarz JT, et al. Treatment of unruptured brain arteriovenous malformations: a single-center experience of 86 patients and a critique of the a randomized trial of unruptured brain arteriovenous malformations (ARUBA) trial. World Neurosurg 2018;110:156–62. doi:10.1016/j.wneu.2018.09.025.
[4] Fukuda K, Majumdar M, Masoud H, et al. Multicenter assessment of morbidity associated with cerebral arteriovenous malformation hemorrhages. J Neurointerv Surg 2017;9:664–8. doi:10.1136/neurintsurg-2016-012483.
[5] Mohr JP, Parides MK, Staf Ic, et al. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial. Lancet 2014;383:614–21. doi:10.1016/s0140-6736(13)62302-8.
[6] Joyce C, Gomez CR. Reimagining ARUBA: theoretical optimization of the treatment of unruptured brain arteriovenous malformations. J Stroke Cerebrovasc 2018;(no pagination). doi:10.1016/j.jstrokecerebrovasc.2018.07.007.
[7] Rutledge WC, Abla AA, Nelson J, Halbach VV, Kim H, Lawton MT. Treatment and outcomes of ARUBA-eligible patients with unruptured brain arteriovenous malformations at a single institution. Neurosurg Focus 2014;37:E8. doi:10.3171/2014.7.FOCUS14242.
[8] Pierot I, Januel AC, Herbreteau D, et al. Endovascular treatment of brain arteriovenous malformations using a liquid embolic agent: results of a prospective multicentre study. Interv Neuroradiol 2013;23:2838–45. doi:10.1007/s00333-013-2870-6.
[9] Solomon R, Connolly ES. Cerebrovascular malformations of the brain. N Engl J Med 2017;377:497–8. doi:10.1056/NEJMct1707399.
[10] Penn DL, Wu KC, Pesswood KR, et al. General principles for preoperative planning and microsurgical treatment of pediatric brain arteriovenous malformations: 2-dimensional operative video. Oper Neurosurg (Hagerstown, MD) 2019;16:E1144. doi:10.1093/ons/opy206.
[11] Tong X, Wu J, Cao Y, Zhao Y, Wang S, Zhao J. Microsurgical outcome of unruptured brain arteriovenous malformations: a single-center experience. World Neurosurg 2017;99:644–55. doi:10.1016/j.wneu.2016.12.088.
[12] Rohn B, Hänggi D, Emmin N, Turowski B, Steiger HJ. Relief of epilepsy and headache and quality of life after microsurgical treatment of unruptured brain AVM—audit of a single-center series and comprehensive review of the literature. Neurosurg Rev 2017;40:59–65. doi:10.1007/s10143-016-0750-7.
[13] Higgins JPT, Altman DJ, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. doi:10.1136/bmj.d5928.
[14] Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 2003;73:712–6.
[15] Ofek Shlomai N, Rao S, Patole S. Efficacy of interventions to improve hand hygiene compliance in neonatal units: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis 2015;34:887–97. doi:10.1007/s10096-015-2313-1.
[16] Chen CJ, Lee CC, Kano H, et al. Radiosurgery for unruptured intervention – naïve pediatric brain arteriovenous malformations. Neurosurgery 2020;87:368–76. doi:10.1093/neuros/nyz558.
[17] Qureshi AI, Saeed O, Sahito S, et al. Treatment outcomes of endovascular embolization only in patients with unruptured brain arteriovenous malformations: a subgroup analysis of ARUBA (a randomized trial of unruptured brain arteriovenous malformations). AJNR Am J Neuroradiol 2020;41:76–80. doi:10.3174/ajnr.A6443.
[18] Ozpar R, Nas OF, Flackkurt K, Taskapilioglu MO, Kocaeli H, Hakyemez B. Endovascular treatment of intracranial arteriovenous malformations using detachable-tip microcatheters and Onyx 18®. Diagn Interv Imaging 2019;100:353–61. doi:10.1016/j.diii.2019.01.009.
[19] Chen CJ, Ding D, Wang TR, et al. Microsurgery versus stereotactic radiosurgery for brain arteriovenous malformations: a matched cohort study. Neurosurgery 2019;84:696–708. doi:10.1093/neuros/nyz174.
[20] Baharudvala H, Blanc B, Fahed R, et al. Endovascular treatment for low-grade (Spetzler–Martin I-II) brain arteriovenous malformations. AJNR Am J Neuroradiol 2019;40:668–72. doi:10.3174/ajnr.A5988.
[21] Karlsson B, Jokura H, Yang HC, et al. The NASSAU (new assessment of cerebral arteriovenous malformations yet unruptured) analysis: are the results from the ARUBA trial also applicable to unruptured arteriovenous malformations deemed suitable for gamma knife surgery? Neurosurgery 2019;85:E118–24. doi:10.1093/neuros/nyz391.
[22] Yang W, Porras JL, Xu R, et al. Comparison of hemorrhagic risk in intracranial arteriovenous malformations between conservative management and embolization as the single treatment modality. Neurosurgery 2018;82:92–9. doi:10.1093/neuros/nyy174.
[23] Starke RM, Ding D, Kano H, et al. International multicenter cohort study of pediatric brain arteriovenous malformations. Part 2: Outcomes after stereotactic radiosurgery. J Neurosurg Pediatr 2017;19:136–48. doi:10.3171/2016.9.PEDS16284.
[24] Stroger U, Hemelsoet D, Vanlangenhove P, et al. Unruptured brain arteriovenous malformations: primary ONYX embolization in ARUBA (a randomized trial of unruptured brain arteriovenous malformations)-eligible patients. Stroke 2017;48:3393–6.
[26] Mohr JP, Overby JR, von Kummer R, et al. Functional impairments for outcomes in a randomized trial of unruptured brain AVMs. Neurology 2017;89:1499–506. doi:10.1212/WNL.0000000000004532.

[27] Ding D, Strake RM, Kano H, et al. Stereotactic radiosurgery for ARUBA (a randomized trial of unruptured brain arteriovenous malformations)—eligible Spetzler–Martin grade I and II arteriovenous malformations: a multicenter study. World Neurosurg 2017;102:2–5. doi:10.1016/j.wneu.2017.03.061.

[28] Ding D, Strake RM, Kano H, et al. Radiosurgery for unruptured brain arteriovenous malformations: an international multicenter retrospective cohort study. Neurosurgery 2017;80:888–98.

[29] Javadpour M, Al-Mahfoudh R, Mitchell PS, Kirollos R, et al. Outcome of microsurgical excision of unruptured brain arteriovenous malformations in ARUBA-eligible patients. Br J Neurosurg 2016;30:619–22. 10.1080/02688697.2016.1181153.

[30] Ding D, Strake RM, Kano H, et al. Radiosurgery for cerebral arteriovenous malformations in a randomized trial of unruptured brain arteriovenous malformations (ARUBA) – eligible patients: a multicenter study. Stroke 2016;47:342–9.

[31] Potts MB, Lau D, Abla AA, et al. Current surgical results with low-grade brain arteriovenous malformations. J Neurosurg 2015;122:912–20.

[32] Morgan MK, Assaad N, Korja M. Surgery for radiosurgery Spetzler–Martin grade 3 brain arteriovenous malformations: a prospective surgical cohort. Neurosurgery 2015;77:362–9. discussion 369–370.

[33] Ding D, Yen C-P, Starke RM, Xu Z, Sheehan JP. Effect of prior hemorrhage on intracranial arteriovenous malformation radiosurgery outcomes. Cerebrovasc Dis 2015;39:53–62. doi:10.1159/000369959.

[34] Ding D, Xu Z, Yen C-P, Starke RM, Sheehan JP. Radiosurgery for unruptured cerebral arteriovenous malformations in pediatric patients. Acta Neurochir 2015;157:281–91. doi:10.1007/s00701-014-2305-4.

[35] Wang Y-C, Huang YC, Chen HC, et al. Linear accelerator stereotactic radiosurgery in the management of intracranial arteriovenous malformations: long-term outcome. Cerebrovasc Dis 2014;37:342–9. doi:10.1159/000360756.

[36] Ding D, Yen C-P, Xu Z, Starke RM, Sheehan JP. Radiosurgery for patients with unruptured intracranial arteriovenous malformations clinical article. J Neurosurg 2013;118:958–66. doi:10.1227/JNS1.0b013e318251825.

[37] Moffatkar P, Hauptman J, Malkadian S, Martin NA. Cerebral arteriovenous malformations. Part 2: physiology. J Neurosurg 2009;102:611–11. doi:10.1227/01.jns.0000334417.56742.24.

[38] Yang S-Y, Kim DG, Chung H-T, Paek SH. Radiosurgery for unruptured cerebral arteriovenous malformations long-term seizure outcome. Neurology 2012;78:1292–8. doi:10.1212/01.wnl.0000381258.1825.

[39] van Beijnum J, van der Worp HB, Buis DR, et al. Treatment of brain arteriovenous malformations with n-butyl cyanoacrylate or Onyx: a meta-analysis. J Neurointerv Surg 2016;8:265–72. doi:10.1136/neurintsurg-2014-011427.

[40] Hong CS, Peterson EC, Ding D, et al. Intervention for a randomized trial of unruptured brain arteriovenous malformations (ARUBA) – eligible patients: an evidence-based review. Clin Neurol Neurosurg 2016;150:133–8. doi:10.1016/j.clineuro.2016.09.007.

[41] Steiger HJ, Schaller K. Treatment of unruptured brain AVM in the aftermath of ARUBA and the Scottish Audit of Intracranial Vascular Malformations. Acta Neurochir (Wien) 2015;157:1291–3. doi:10.1007/s00701-015-2477-6.

[42] Cohen-Inbar O, Ding D, Sheehan JP. Stereotactic radiosurgery for deep intracranial arteriovenous malformations, part 2: basal ganglia and thalamus arteriovenous malformations. J Clini Neurosci 2016;24:37–42.

[43] Chang SD, Shuster DT, Steinberg GK, Levy RP, Frankel K, et al. Stereotactic radiosurgery of arteriovenous malformations: pathologic changes in resected tissue. Clin Neuropathol 1997;16:111–6.

[44] Kida Y, Kobayashi T, Tanaka T, Mori Y, Hasegawa T, Kondoh T. Seizure control after radiosurgery on cerebral arteriovenous malformations. J Clini Neurosci 2000;7(suppl 1):6–9. doi:10.1054/jcnn.2000.0701.

[45] Eisenschenk S, Gilmore RL, Friedman WA, Henchey RA. The effect of LINAC stereotactic radiosurgery on epilepsy associated with arteriovenous malformations. Stereotact Funct Neurosurg 1998;71:51–61. doi:10.1159/000029648.

[46] Flickinger JC, Kondziolka D, Lunsford LD, et al. Development of a model to predict permanent symptomatic postradiosurgery injury for arteriovenous malformation patients. Arteriovenous Malformation Radiosurgery Study Group. Int J Radiat Oncol Biol Phys 2000;46:1143–8. doi:10.1016/s0360-3016(99)00513-1.

[47] Morgan MK, Davidson AS, Assaad NNA, Stoodley MA. Critical review of brain AVM surgery, surgical results and natural history in 2017. Acta Neurochir 2017;159:1457–78.

[48] Mohr JP, Overby J, Stapp G, et al. Clinical impairment in patients followed with or without interventional therapy in a randomized trial of unruptured brain AVMs (aruba). Stroke 2016;47:

[49] Xu H, Wang L, Guan S, Li D. Embolization of brain arteriovenous malformations with the diluted Onyx technique: initial experience. Neuroradiology 2019;61:871–8.

[50] Thomas JM, Surendran S, Abraham M, Rajavelu A, Kartha CC. Genetic and epigenetic mechanisms in the development of arteriovenous malformations in the brain. Clin Epigenetics 2016;8:78doi:10.1186/s13148-016-0248-8.

[51] Chen X, Liu Y, Zhou S, et al. Methylation of the CDKN2A gene increases the risk of brain arteriovenous malformations. J Mol Neurosci 2019;66:23. doi:10.1007/s12031-019-01360-6.

[52] Nakamura Y, Sugita Y, Nakashima S, et al. Alternately activated macrophages play an important role in vascular remodeling and hemorrhaging in patients with brain arteriovenous malformations. J Stroke Cerebrovas Dis 2016;25:600–9. doi:10.1016/j.jstrokecerebrovasdis.2015.11.034.

[53] Cao J, Yang R, Smith TE, et al. Human umbilical tissue-derived cells secrete soluble VEGF1 and inhibit choroidal neovascularization. Mol Ther Methods Clin Dev 2019;14:37–46. doi:10.1016/j.therapev.2019.05.007.

[54] Jabbour MN, Elder JB, Samuelson CG, et al. Aberrant angiogenic characteristics of human brain arteriovenous malformation endothelial cells. Neurosurgery 2009;64:139–46. discussion 146–139. doi:10.1227/01.Neu.0000334417.36742.24.

[55] Wang K, Zhao S, Liu B, et al. Perturbations of BMP/PTG-beta and VEGF/VEGFR signalling pathways in non-syndromic sporadic brain arteriovenous malformations (BAVM). J Med Genet 2018;55:675–84. doi:10.1136/jmedgenet-2017-105224.

[56] Gorozhanin VA, Eliava SS, Filipenko YV, Shekhtman OD, Sazonova OBA. A Comprehensive study of symptomatic late radiation-induced complications after radiosurgery for brain arteriovenous malformation: incidence, risk factor, and clinical outcomes. Zhurnal voprosy neurohirurgii imeni N N Burdenko 2018;82:30–7. doi:10.17116/neuro20188206130.